Skip to main content

China COVID-19 Vaccines and Antibody Treatments Advancing toward Approvals

Chris Chen, CEO at Shanghai-headquartered WuXi Biologics, told a reporter that the CRO/CMO is working on 10 neutralizing antibodies from clients for COVID-19 and one vaccine. Because the candidates are making rapid progress, he expects approval for a COVID-19 antibody treatment either “late this year or early next year.” Meanwhile, Sinopharm said three unapproved China vaccines, two of its own and one from Sinovac, have been administered to one million people in China who face exposure to COVID-19. More details.... Stock Symbol: (HK: 2269) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.